Abstract This document describes the recommendations of a group of scientific societies concerning the first-line therapeutic approach to paediatric tuberculosis (TB). The treatment of pulmonary TB should be based on the existence of parenchymal involvement and the risk of antibiotic resistance. The treatment of extra-pulmonary TB is based on the regimens used for severe pulmonary TB. The administration of corticosteroids is recommended only in cases of miliary TB, tuberculous meningitis and tuberculous pericarditis. Vitamin B6 may be indicated in the case of isoniazid-treated TB in breastfeeding infants, severely malnourished subjects, or patients with other diseases at high risk of vitamin deficiency. Once having started treatment, children with TB should be carefully followed up in order to evaluate compliance, the response to treatment, the need for treatment changes, and the presence of drug-related adverse events. Primary care paediatricians can support reference centres in providing family healthcare education and encouraging treatment compliance.
Introduction
Tuberculosis (TB) is the second highest cause of death due to infectious diseases worldwide. It has been estimated that about 550,000 of the estimated nine million worldwide incident cases of TB in 2013 (about 6 % of the total) were cases affecting under 15-year-olds, and that TB caused the death of about 80,000 HIV-negative children (range 64,000-97,000) [1, 2] . However, a recent mathematical modelling study on childhood TB in 22 high-burden countries supports the view that World Health Organization (WHO) statistics are an underestimate, as these numbers are based on notified cases [3] .
The therapeutic management of paediatric TB is complicated by the fact that many potentially useful drugs are not registered for paediatric use and there are no formulations suitable for the first years of life [4] .
This document describes the recommendations of a group of scientific societies concerning the first-line therapeutic approach to paediatric TB. The effects of human immunodeficiency virus (HIV) co-infection and other immunodeficiencies on TB treatment and management of drug-resistant TB have been evaluated in two other papers.
Methodology
Using the Consensus Conference method based on the National Institutes of Health and the Italian National Programme guidelines [5, 6] (Table 1) The evidence review procedures focused on patients aged 0-18 years and included section-specific targeted searches as well as formal systematic reviews of selected aspects, and the clinical recommendations made in the updated international guidelines were reviewed and critically compared in the case of debated issues. All of the data were entered in tables of evidence for each subject. Trained personnel critically appraised the acquired literature using the Scottish Intercollegiate Guidelines Network methodological checklists [7] , and the bibliographical material and a preliminary draft document were given to the panel members. The published evidence was presented and discussed at various meetings, and the Delphi method was used to reach a consensus when the evidence did not provide consistent and unambiguous recommendations [7] . The final text was revised on the basis of these discussions and submitted by e-mail to participants at the Consensus Conference for final approval.
The multidisciplinary panel of clinicians and experts in evidence-based medicine were identified with the help of the participating scientific societies, and included experts in the fields of general paediatrics, paediatric infectious diseases, neonatology, infectious diseases, pneumology, microbiology, radiology, pharmacology and methodology. The panel was coordinated by the Italian Society of Pediatric Infectious Diseases (SITIP). No panel member declared any conflict of interest concerning the contents of the guideline topics. The panel met on three occasions, but many of the consultations involved in developing the document took place interactively by e-mail or telephone.
What is the Basic Treatment for Paediatric
Pulmonary Tuberculosis (TB)?
In the absence of ascertained or suspected drug-resistant TB, the treatment of tuberculous pneumonia and all of the other clinical manifestations of TB is based on four drugs: isoniazid, rifampin, pyrazinamide and ethambutol [8] [9] [10] . These are used in combinations that always include isoniazid and rifampin, with the others being added depending on the specific clinical situation. The use of multiple drugs arises from the need to eradicate the disease-causing mycobacteria as rapidly as possible and avoid the emergence of resistance, which is the main cause of relapses and therapeutic failures. Bactericidal drugs (particularly isoniazid) are capable of eradicating the rapidly multiplying bacteria that give rise to the acute phase of the disease and are therefore immediately beneficial for patients, whereas bacteriostatic drugs (particularly pyrazinamide) complete the sterilisation of infectious foci by mainly acting on the bacilli with a low level of metabolic activity that are responsible for persistent disease and possible relapses. The simultaneous administration of drugs with different targets and mechanisms of action significantly reduces the possibility of bacterial selection and the emergence of resistance. The regimens used to treat paediatric pulmonary TB vary depending on (a) the severity of the disease; (b) whether it represents the first or a subsequent treatment of TB; and (c) whether the patient comes from an area with a low or high prevalence of drug-resistant tuberculous bacteria.
The initial characterisation of the type of pulmonary TB is therefore essential in order to identify the most appropriate treatment [8] [9] [10] , and should be started as soon as possible, even in the case of just a well-founded suspicion. The treatment of mild forms with limited parenchymal involvement diagnosed in subjects living in areas with a low prevalence of bacterial resistance is based on the administration of isoniazid, rifampin and pyrazinamide for 2 months (intensive phase), followed by treatment with isoniazid and rifampin for a further 4 months (continuation phase) [8] [9] [10] .
In severe forms with extensive pulmonary involvement, or mild forms with a high risk of antibiotic resistance, ethambutol should be added to the other three drugs during the intensive 2-month phase [8] [9] [10] . The reasons for using four drugs is that it can be presumed that the bacterial load is greater and it is necessary to eliminate the mycobacteria that replicate slowly as quickly as possible. However, as in the case of mild forms, the continuation phase requires only two drugs (rifampin and isonazid) for 4 months as it has been shown that there is no difference in the cure and relapse rates between 4 and 7 months' continuation treatment [4, [8] [9] [10] .
The same regimens can be administered in subjects of all ages, including those \9 years old who were once not administered ethambutol because of the impossibility of monitoring its toxicity [2, 11] . However, this limitation no longer applies as it has been demonstrated that the risk of optic neuritis (the most serious adverse event) is practically zero provided that the currently recommended dose (20 mg/kg/day) is respected and the treatment is limited in time, as is the case with the regimens currently recommended for patients treated for the first time.
It used to be said that, regardless of the severity of the disease, the drugs used during the continuation phase could be administered three times a week rather than every day provided that the doses were adjusted and treatment compliance was closely monitored [12] . However, the difficulties of monitoring and the fact that just one missed administration can have a considerable impact on the continuity of the treatment have led many authors to exclude this possibility in paediatrics. Table 2 summarises the paediatric pulmonary TB treatment regimens.
The paediatric doses of the drugs used in the first-line treatment of TB used to be related to those used in adults, but a number of pharmacokinetic studies have demonstrated that administering the same dose per kilogram of body weight to children and adults leads to very different blood and tissue drug concentrations, which are lower in children, especially during the first years of life [4, 8, 10, 13, 14] . As this increases the risk that the treatment may not be sufficient to eradicate the infectious pathogens, the WHO has recently revised the recommended doses by doubling the paediatric dose of isoniazid and increasing those of rifampin, pyrazinamide and ethambutol, while keeping them within demonstrated safe and tolerable ranges for which evidence was available (Table 3) .
However, despite these changes, it is still more difficult to administer the correct dose to children for two reasons. The first is that there is no suspension formulation of pyrazinamide alone or ethambutol alone [4, 8, 11] , which means that they have to be administered in tablet form or as a home-made preparation suitable for children who are too young to be able to swallow tablets. In either case, but particularly in the case of tablets, it is inevitable that the administered dose may be different from that desired. This situation is made even more complicated by the fact that, especially in the youngest patients, a favourable therapeutic response often leads to a rapid increase in weight and so the daily dose has to be frequently adjusted, which can be difficult because of the lack of appropriate formulations. The other problem is that, in order to encourage treatment compliance in adults with TB, some tablets contain two or more of the first-line drugs, and the concentrations of these are not necessarily suitable for children. One example of this is the marketed formulation of tablets containing rifampin and isoniazid in a concentration ratio of 2:1, whereas the recommended paediatric ratio is 1.5:1. This means that additional doses of isoniazid have to be administered, and leads to the further risk that the final dose actually given is different from the prescribed dose. In order to overcome these limitations, the WHO has indicated that that the ideal treatment during the intensive phase of severe forms of TB should consist of easily dispersible tablets containing isoniazid 250 mg, rifampin 250 mg, pyrazinamide 400 mg and ethambutol 250 mg [8] . For mild forms, it would be useful to have a preparation of isoniazid 150 mg, rifampin 250 mg and pyrazinamide 400 mg, whereas a two-ingredient product with rifampicin 250 mg and isoniazid 150 mg would be ideal during the continuation phase. Interestingly, new fixed-dose combinations in dispersible formulation with flavours of mango, strawberry, and raspberry that include rifampin 75 mg ? isoniazid 50 mg ? pyrazinamide 150 mg or rifampin 75 mg ? isoniazid 50 mg have been developed by TB Alliance and will be soon available in the market [15] .
All of these data indicate that paediatric prescriptions of first-line drugs need to be checked more frequently and more carefully than is normally done in the case of adults.
What is the Treatment for Paediatric ExtraPulmonary TB (EPTB)?
The treatment of EPTB is similar to that for severe pulmonary TB at least partially because there is a lack of disease-specific studies of regimens based on different drug combinations or doses. Except for tuberculous lymphadenitis, for which isoniazid, rifampin and pyrazinamide can be used, the recommended treatment is four drugs for the first 2 months (isoniazid, rifampin, pyrazinamide and ethambutol), followed by isoniazid and rifampin for 4 months [9] . In the case of tuberculous meningitis (TBM), prescribers should consider the limited capacity of some of the drugs to cross the blood/brain barrier in order to reach the site of infection and therapy should be maintained for 9-12 months [2, 12, 16] .
As there are very few adequately conducted studies of paediatric TBM, the official recommendations of scientific societies are based more on the judgement of experts than the results of clinical trials [2, 10, 17, 18] ; but, in any case, the severity of the disease always requires initial treatment with four drugs (Table 4) . Isoniazid, rifampin and pyrazinamide remain the primary drugs [16, 17] , of which isoniazid probably has the greatest effect because, in addition to its antimicrobial activity, it is capable of crossing the blood/brain barrier at above-minimum inhibitory concentrations even at the same doses as those used to treat pulmonary TB [11, 16] . In contrast, rifampin enters cerebrospinal fluid (CSF) at concentrations that are no more than 10 % of those found in plasma. It has been demonstrated that the administration of 10 mg/kg/day (the minimum recommended dose for pulmonary TB) leads to CSF concentrations of \1 lg/mL, which are often insufficient to eradicate the bacteria [11, 12] . Consequently, it is recommended to use the maximum recommended doses for children weighing \10 kg, and at least 15 mg/kg for those weighing 10-20 kg. Pyrazinamide has good CSF penetration and can therefore be used at doses that are similar to those used for severe pulmonary TB, while remembering that maximum doses should be used in the youngest subjects [11, 12] .
The fourth antibiotic is usually ethambutol [10] [11] [12] 16] . This drug has a limited ability to cross the blood/brain barrier and, as it has little bactericidal activity, probably does not contribute much to sterilising CSF; however, it does have a protective effect on the simultaneously administered anti-TB agents and reduces the risk of the emergence of resistance.
In the case of the onset of hydrocephalus, surgery firstly with external ventricular drains and then with ventriculoperitoneal shunts may be necessary in addition to medical therapy [12] .
When Should Steroids Be Administered?
TB is often accompanied by a strong immune response against the tuberculous mycobacteria that may per se lead to the onset of a severe inflammatory process that can cause [12] . This is the rationale underlying the practice of combining antibiotic therapy with the potent anti-inflammatory activity of corticosteroids. However, although these are widely used to treat all of the clinical forms of TB, the only certain (and overwhelmingly adult) data concerning their efficacy relate to TBM, tuberculous pericarditis, and miliary TB [8] . Only one adequately conducted study has demonstrated their usefulness in endobronchial TB [8] , whereas only uncontrolled studies or clinical case studies have reported that steroids have positive effects in cases of endothoracic lymphadenitis causing significant bronchial compression or mediastinic syndrome, tuberculomas with neurological manifestations, and the more severe forms of miliary TB [8] . The use of steroids for other forms of TB (particularly pneumonia and peripheral lymphadenitis) is not considered useful and is not recommended [8] . The same is also true of pleurisy because, although they seem to provide an initial advantage by rapidly resolving effusion and its related symptoms, they do not change the risk of fibrosis and pleural thickening [8] .
Various compounds have been tried but it is not known which corticosteroid leads to the best results or which regimen offers the best guarantee as there is a lack of comparative studies. On the basis of the available data, it is possible to suggest administering an oral steroid at a high dose for 3-4 weeks and then tapering it to discontinuation over the next 1-4 weeks [12] (Table 5 ). Given the use of high doses, adverse events need to be carefully monitored and the doses should be reduced as soon as the clinical symptoms allow.
Should Vitamins Be Given to Children
Undergoing Anti-TB Treatment?
There are two vitamins that can be considered under particular circumstances: vitamin B6 and vitamin D [19] . The possible need for vitamin B6 supplementation arises because isoniazid, a pivotal drug the treatment of TB, binds to vitamin B6 and thus reduces circulating levels [20, 21] .
As it is essential for the synthesis of synaptic neurotransmitters, vitamin B6 deficiency can lead to the onset of peripheral neuritis, ataxia and paresthesia; however, numerous studies have shown that the neurological problems associated with the administration of isoniazid are very rare in children even if their blood vitamin levels are lower than normal, especially if they receive maximum doses [19] . Consequently, supplementation with 5-10 mg/day is only recommended for breastfed infants or in cases in which it can be presumed that the vitamin deficiency is due to serious nutritional problems or caused by an underlying disease including HIV infection. The use of vitamin D is suggested because, in addition to regulating bone metabolism, it also modulates innate and acquired immunity, and low blood levels have been associated with a greater risk of various infectious diseases, including respiratory diseases [22] . As low levels have been found in children with TB [23] , it has been investigated whether the administration of vitamin D may favour cure and reduce the risk of therapeutic failures and relapses. However, the few paediatric findings are conflicting: some of the data are positive but there are other data that seem to indicate the total inefficacy of supplementation [24] . Studies in adults have shown that a vitamin D regimen safely corrected vitamin D deficiency, but did not improve the clinical findings and time to sputum culture conversion in patients with pulmonary TB [25, 26] . The difficulty of evaluating the possible role of vitamin D in the treatment of TB is compounded by the fact that it is still unclear what minimum level should be considered normal in individual subjects, what supplementary dose should be administered in order to reach apparently adequate blood concentrations for the age and racial characteristics of the child, and in what period of the year it should be administered. Systematic vitamin D supplementation therefore cannot be recommended until further studies have been carried out. The toxicity of the first-line antibiotics used to treat TB is much less in children (especially those in their first years of life) than in adults [8, 9] for a number of reasons. The main reason is that these antibiotics are partly or wholly metabolised in the liver by means of mechanisms that are much more efficient in early life than later. This means that, if children and adults are administered the same dose per kilogram of body weight, blood and tissue antibiotic levels are much lower in the former, thus leading to less risk of toxicity albeit at the cost of a reduction in efficacy. However, this is not the only factor as is shown by the fact that the recent recommendation of the WHO to use much higher doses for children than those previously prescribed in order to overcome the risk to therapeutic efficacy does not seem to have significantly increased the risk of toxicity [8] .
Other conditioning factors are that children are less likely to be suffering from concomitant liver diseases, and that paediatric TB is generally less severe and requires less complex treatment [8] . It has been shown that adverse events are less frequent in subjects with liver diseases due to causes other than TB, those who have particularly severe forms of TB, and those treated with a large number of drugs at the maximum doses of each.
However, all of the first-line anti-TB drugs can give rise to adverse events [8] and, given that they are administered in combinations, it is often difficult to determine which is responsible for the onset of signs and symptoms, especially when the clinical picture may be due to more than one. For example, liver damage (the most frequent adverse event caused by first-line antibiotics) may be due to isoniazid, rifampicin or pyrazinamide, although it is more likely to be caused by isoniazid [27, 28] . The data concerning the liver toxicity of isoniazid, most of which come from studies of adverse events experienced by subjects who have been treated by isoniazid alone for latent tubercular infection, show that the risk of drug-related liver damage is essentially low and, above all, not very severe insofar as it mainly consists of a limited increase in transaminases without any other clinical manifestations. Such an increase occurs in 5-10 % of treated patients, and is more frequent in adolescents and patients receiving maximum doses [27, 28] . In any case, the levels rarely exceed five times the upper normal limit, very often normalise spontaneously even if the treatment is continued unchanged, and the appearance of jaundice or manifestations of liver insufficiency is very rare [27, 28] . The elimination of isoniazid is subject to the influence of the N-acetyltransferase 2 (NAT2) genotype, and individuals may be homozygotic slow, heterozygotic fast, or homozygotic fast acetylators of isoniazid [29] . Slow-acetylator status of NAT2 is a significant susceptibility risk factor for anti-TB drug-induced hepatitis and slow acetylators are prone to develop more severe hepatotoxicity than rapid acetylators [29, 30] . Hepatic damage due to rifampicin and pyrazinamide is less frequent than that reported for isoniazid, also mainly expressed by a generally slight increase in transaminase levels, and tends to regress spontaneously even during treatment [8] . Donald highlighted that the use of the higher dosages of isoniazid, rifampin, and pyrazinamide recently recommended by WHO is unlikely to result in a greater risk of drug-related hepatotoxicity in children treated for TB [28] .
Other adverse events attributable to isoniazid are neurological manifestations, mainly peripheral neuritis secondary to the vitamin B6 deficiency caused by antibiotic binding to the vitamin and the consequent suppression of its functions [20, 21] . As vitamin B6 is essential for synaptic neurotransmitter synthesis, the deficiency leads to peripheral neuritis, ataxia and paresthesia. These alterations are dose dependent but very rarely appear in children. All of the studies show that even doses of 15 mg/ kg/day do not give rise to any clinical problems except in the case of nutritional deficiency or underlying situations such as breastfeeding or the presence of a disease that itself causes vitamin deficiency [19] .
Allergic manifestations secondary to the use of rifampin are very rare and of little clinical importance [19] . They are more frequent when the drug is used intermittently and at high doses.
The main adverse event due to ethambutol is optic neuritis, a very serious disease that is fortunately reversible if diagnosed early [12] . However, it is difficult to diagnose in uncooperative children because the fundus of the eye appears normal when examined ophthalmoscopically and the signs of toxicity are a reduction in visual acuity, the perception of colour and the visual field, none of which are detectable in children in the first years of life. The frequency of ocular alterations depends on the administered dose and the duration of therapy, but the available paediatric data indicate that the risk is extremely low even when the maximum recommended dosages are used throughout the 2 months of the attack phase [10] . Even at doses of 15-25 mg/kg/day, the risk is less than 1/1000. However, a recent retrospective study conducted in France showed that alterations in visual function related to the use of ethambutol are not uncommon in young children and are most likely underestimated [31] . On the basis of these findings, the authors suggested a systematic close monitoring using visual-evoked potentials in young children treated with ethambutol [31] . Streptomycin and the aminoglycosides in general can give rise to ototoxicity and renal damage [10] , and are difficult to use in children because of their necessarily parenteral administration adverse effects. A key strategy in minimising toxicity and optimising therapy during aminoglycoside use is therapeutic drug monitoring. Table 6 summarises the main adverse effects attributed to first-line anti-TB drugs.
9 How Should Children Receiving First-Line Anti-TB Drugs Be Monitored?
After the start of treatment, the symptoms of TB (fever, cough, loss of appetite and weight loss) gradually decline and disappear within 2-4 weeks [9, 10] . Severe pulmonary TB and extra-pulmonary forms involving the CNS and skeletal system take longest to respond to treatment [9, 10] . Children with confirmed TB who continue to present symptoms despite well conducted treatment and the certainty of absolute compliance with the recommendations should be considered probable therapeutic failures and candidates for treatment with second-and third-line drugs [9, 10] . Clinical management depends on the type of TB and its severity. Patients with mild pulmonary forms generally do not require strict supervision and can be followed up 2 weeks after starting treatment and, if the course of the disease is favourable, at the end of the intensive phase and every 2 months during the continuation phase [9, 10] . Every examination should consist of an assessment of symptoms; an analysis of the patient's general condition, including a measurement of weight; an evaluation of treatment compliance by means of direct observation of the mode of administration; possible changes in drug doses depending on variations in weight; an analysis of potentially drug-related adverse events; and possible changes in drug type as a consequence of the appearance of adverse events.
The efficacy of the treatment of open forms should be checked microbiologically by evaluating expectorate and/ or gastric aspirate 2-4 weeks after the start of therapy, and at the end of the intensive phase [9, 10] .
Radiological examinations are not usually necessary in the case of mild pulmonary forms with a favourable course throughout the period of treatment [9, 10] , but may be useful at the end of treatment in order to confirm a complete cure. In severe cases, they should be carried out at regular intervals depending on the type of disease [9, 10] .
No measures are required in the case of asymptomatic hypertransaminasemia provided that transaminase levels do not exceed five times the upper normal limit; in the presence of symptoms, this becomes three times the upper normal limit [32] . In both cases, the intervention consists of discontinuing all of the previously administered hepatotoxic drugs (isoniazid, rifampin, pyrazinamide). It is advisable not to resume them until all of the manifestations of hepatitis (jaundice and increased enzyme levels) have disappeared and then to administer the potentially responsible antibiotics one at a time in order to verify the tolerability of each [32] . Vitamin B6 should be administered to isoniazid-treated patients developing peripheral neuritis [20, 21] .
If a child treated with ethambutol experiences visual disturbances, the drug should be discontinued and, if he or she is capable of collaborating, an ophthalmological examination should be arranged [31] .
How Should Treatment Compliance Be
Monitored, and How Often?
Compliance with the treatment of TB is essential not only in order to ensure that the patient is cured, but also in order to prevent the spread of infection and the emergence of bacterial resistance [33, 34] . The long duration of treatment, the possible occurrence of adverse events, a limited understanding of the importance of drugs in ensuring the favourable evolution of the infection or disease, difficulties in reaching the clinic responsible for carrying out the follow-up examinations or in establishing confidential relationships with healthcare staff are all factors that can negatively affect compliance, which explains why health authorities throughout the world are interested in introducing control systems aimed at verifying that patients take their drugs as prescribed throughout the planned treatment period [33, 34] . The most frequently recommended system is direct verification of what drugs are taken and at what doses. The WHO indicates directly observed therapy (DOT) as the most suitable means, and has included it in its public health programme for controlling TB in the world [33, 34] . Although it may be implemented in different ways, the DOT method requires patients to take their prescribed drugs under the eyes of healthcare staff a number of times during the intensive phase and at least once during the continuation phase. The staff check that the drugs are taken correctly and correct any errors, making sure that the patient and his/her caregiver have understood. In order to make the system work well, the availability of the drug(s) is constantly checked and the therapeutic situation is continuously monitored in such a way as to identify any discontinuation of treatment and the reasons for it.
However, as many of the studies designed to verify the real impact of this method have not found any significant advantages [32] , it is suggested that further measures aimed at increasing compliance should be agreed before starting treatment. Some of these measures are aimed directly at patients, including (a) patient and parent educational programmes mainly designed to explain the problems and difficulties of anti-TB treatment in detail, paying particular attention to the strict correlation between optimal treatment and therapeutic success; (b) telephone, post and e-mail reminders of appointments at the reference centres for follow-up examinations and verification of treatment compliance; (c) economic incentives to attend the appointments, including the reimbursement of travelling expenses; and (d) hospitalisation when non-compliance is identified and other methods have proved to be ineffective. Other measures are directed at healthcare personnel and essentially involve educational programmes designed to strengthen their motivation and encourage a more appropriate approach to patients that ensures they are given complete and correct information about TB treatment and the need to comply with prescriptions exactly.
Pharmacological measures include the simplification of treatment (although this approach is discouraged in the paediatric population, especially if HIV infected), the direct management of antibiotic supplies by prescribing physicians, and periodic urine analyses in order to check for drug presence [32] . The use of incentives in order to increase the interest of patients and their parents in the treatment of TB is impracticable in many countries, including Italy, and hospitalisation must be considered an extreme option that is burdened by many contraindications, and should therefore only be used when everything else has failed or is destined to fail for socio-economic reasons.
As far as pharmacological changes are concerned, the suggestion of thrice-weekly drug administration is very debatable because missing even one day means losing half a week of therapy, whereas the once-daily administration of fixed drug combinations seems to be more practical.
There are also problems in assessing urinary drug excretion because, in addition to being very approximate and only feasible in the case of rifampicin and isoniazid, it may even be dangerous [12] because detecting isoniazid requires the use of potassium cyanide, which is only qualitative and certainly not easy to handle.
In conclusion, although important, perfect compliance with prescribed anti-TB treatment regimens is difficult to obtain even when drug intake is directly controlled. However, the addition of information and sensitisation programmes that make patients and healthcare staff more aware of the problem, and the activation of systems that facilitate relationships between medical centres and users, can lead to greater acceptance.
What is the Role of Primary Care
Paediatricians?
The need for the active involvement of the family (and the patient if old enough) implies intensive educational activity that cannot be left exclusively on the shoulders of the staff of the reference centre attended by children with TB, but requires the support of the patient's general practitioner (GP) or primary care paediatrician. The effectiveness of treatment is closely related to the physician-driven motivation and educational level of the family, and their willingness to follow medical advice. Primary care paediatricians and GPs can play a fundamental role by directly checking treatment compliance, which is probably more productive than leaving it up to the reference centre especially if the relationship with the family is good.
Conclusions
After analysing the published evidence and on the basis of their own clinical experience, the group of experts reached the following conclusions:
• The treatment of pulmonary TB with limited parenchymal involvement (mild forms) diagnosed in subjects living in areas that have a low prevalence of bacterial resistance is based on the administration of isoniazid, rifampin and pyrazinamide for 2 months (intensive phase), followed by treatment with isoniazid and rifampin alone for a further 4 months (continuation phase) [I-A].
• In the case of extensive lung involvement (severe forms) or mild TB with a high risk of antibiotic resistance, the first 2 months of treatment should be based on the same three drugs with the addition of ethambutol, and this should be followed by a continuation phase with isoniazid and rifampin for a further 4 months [I-A].
• Paediatric anti-TB therapy should be administered at doses per kilogram of body weight, and should be periodically checked bearing in mind the weight gain of children [I-A].
• With the exception of TBM, the treatment of EPTB is based on the three-or four-drug regimens used for the severe forms of pulmonary TB (isoniazid, rifampin, pyrazinamide ± ethambutol) for 2 months followed by two drugs (isoniazid and rifampin) for 4 months [I-A].
• In the case of TBM, the recommended treatment is represented by four drugs for 2 months (isoniazid, rifampin, pyrazinamide and ethambutol), followed by isoniazid and rifampin for 
